USE OF VERCIGUAT IN THE TREATMENT OF HEART FAILURE
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.4937Keywords:
Vericiguat, Soluble Guanylate Cyclase (sGC) Stymulator, Heart Failure, Pharmacological Treatment, Cardiovascular OutcomesAbstract
Heart failure remains a major challenge in contemporary cardiology, characterized by high morbidity, frequent hospitalizations, and an unfavorable prognosis despite substantial advances in guideline-directed therapy. Although modern multidrug treatment has improved clinical outcomes, a considerable proportion of patients continue to experience disease progression and recurrent exacerbations, particularly in high-risk populations.
Vericiguat is a novel oral agent used in the treatment of heart failure and represents an adjunct to standard therapy in selected patients. To date, clinical studies have evaluated the efficacy and safety of vericiguat in patients with both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. Available evidence suggests that the clinical effects of vericiguat vary depending on the heart failure phenotype and the clinical context, including disease stability and the risk of further deterioration.
This paper provides a comprehensive review of current data on the use of vericiguat across different heart failure phenotypes, with particular emphasis on clinical trial outcomes, therapeutic efficacy, and safety profile. The limitations of existing evidence are discussed, along with the potential role of vericiguat within contemporary treatment strategies. Overall, current findings indicate that vericiguat should not be regarded as a universal therapy for all patients with heart failure, but rather as a complementary treatment option for carefully selected individuals, in whom additional therapeutic strategies may be required.
References
Agha, G., Loucks, E. B., Tinker, L. F., Waring, M. E., Michaud, D. S., Foraker, R. E., Li, W., Martin, L. W., Greenland, P., Manson, J. E., & Eaton, C. B. (2014). Healthy lifestyle and risk of heart failure in the Women’s Health Initiative Observational Study. Journal of the American College of Cardiology, 64(17), 1777–1785. https://doi.org/10.1016/j.jacc.2014.07.981
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner-La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., Piña, I. L., ... EMPEROR-Preserved Trial Investigators. (2021). Empagliflozin in heart failure with a preserved ejection fraction. The New England Journal of Medicine, 385(16), 1451–1461. https://doi.org/10.1056/NEJMoa2107038
Armstrong, P. W., Lam, C. S. P., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., O’Connor, C. M., Pieske, B., Ponikowski, P., Shah, S. J., Solomon, S. D., Voors, A. A., She, L., Vlajnic, V., Carvalho, F., Bamber, L., Blaustein, R. O., Roessig, L., & Butler, J. (2020). Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction. JAMA, 324(15), 1–10. https://doi.org/10.1001/jama.2020.15922
Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., O’Connor, C. M., & VICTORIA Study Group. (2020). Vericiguat in patients with heart failure and reduced ejection fraction. The New England Journal of Medicine, 382(20), 1883–1893. https://doi.org/10.1056/NEJMoa1915928
Behnoush, A. H., Khalaji, A., Naderi, N., Ashraf, H., & von Haehling, S. (2022). ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. ESC Heart Failure, 10(3), 1531–1544. https://doi.org/10.1002/ehf2.14255
Borlaug, B. A., & Paulus, W. J. (2011). Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment. European Heart Journal, 32(6), 670–679. https://doi.org/10.1093/eurheartj/ehq426
Butler, J., McMullan, C. J., Anstrom, K. J., Barash, I., Bonaca, M. P., Borentain, M., Corda, S., Ezekowitz, J. A., Felker, G. M., Gates, D., Lam, C. S. P., Lewis, E. F., Lindenfeld, J., Mentz, R. J., O’Connor, C. M., Ponikowski, P., Reddy, Y. N. V., Rosano, G. M. C., Saldarriaga, C., ... Sasannejad, C. (2025). Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): A double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet, 406(10510), 1341–1350. https://doi.org/10.1016/S0140-6736(25)01665-4
Cao, Y., Sun, Y., Miao, B., Zhang, X., Zhao, Q., Qi, L., Chen, Y., & Zhu, L. (2024). Vericiguat on C-reactive protein level and prognosis in patients with hypertensive heart failure. High Blood Pressure & Cardiovascular Prevention, 31(5), 485–492. https://doi.org/10.1007/s40292-024-00664-y
Carbone, S., Lavie, C. J., Elagizi, A., Arena, R., & Ventura, H. O. (2022). The impact of obesity in heart failure. Cardiology Clinics, 40(2), 209–218. https://doi.org/10.1016/j.ccl.2021.12.009
Chamberlain, A. M., Boyd, C. M., Manemann, S. M., Dunlay, S. M., Gerber, Y., Killian, J. M., Weston, S. A., & Roger, V. L. (2020). Risk factors for heart failure in the community: Differences by age and ejection fraction. The American Journal of Medicine, 133(6), e237–e248. https://doi.org/10.1016/j.amjmed.2019.10.030
Cleland, J. G. F., Daubert, J.-C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., Tavazzi, L., & Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England Journal of Medicine, 352(15), 1539–1549. https://doi.org/10.1056/NEJMoa050496
Czepluch, F. S., Wollnik, B., & Hasenfuß, G. (2018). Genetic determinants of heart failure: Facts and numbers. ESC Heart Failure, 5(3), 211–217. https://doi.org/10.1002/ehf2.12267
Dhingra, R., Gaziano, J. M., & Djoussé, L. (2011). Chronic kidney disease and the risk of heart failure in men. Circulation: Heart Failure, 4(2), 138–144. https://doi.org/10.1161/CIRCHEARTFAILURE.109.899070
Ding, N., Shah, A. M., Blaha, M. J., Chang, P. P., Rosamond, W. D., & Matsushita, K. (2022). Cigarette smoking, cessation, and risk of heart failure with preserved and reduced ejection fraction. Journal of the American College of Cardiology, 79(23), 2298–2305. https://doi.org/10.1016/j.jacc.2022.03.377
Fang, J. C., Ewald, G. A., Allen, L. A., Butler, J., Westlake Canary, C. A., Colvin-Adams, M., Dickinson, M. G., Levy, P., Stough, W. G., Sweitzer, N. K., Teerlink, J. R., Whellan, D. J., Albert, N. M., Krishnamani, R., Rich, M. W., Walsh, M. N., Bonnell, M. R., Carson, P. E., Chan, M. C., ... Heart Failure Society of America Guidelines Committee. (2015). Advanced (stage D) heart failure: A statement from the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 21(6), 519–534. https://doi.org/10.1016/j.cardfail.2015.04.013
Farmakis, D., Parissis, J., Lekakis, J., & Filippatos, G. (2015). Acute heart failure: Epidemiology, risk factors, and prevention. Revista Española de Cardiología, 68(3), 245–248. https://doi.org/10.1016/j.rec.2014.11.004
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., Samano, E. T., Müller, K., Roessig, L., Pieske, B., & SOCRATES-REDUCED Investigators and Coordinators. (2015). Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA, 314(21), 2251–2262. https://doi.org/10.1001/jama.2015.15734
Kemp, C. D., & Conte, J. V. (2012). The pathophysiology of heart failure. Cardiovascular Pathology, 21(5), 365–371. https://doi.org/10.1016/j.carpath.2011.11.007
Khatibzadeh, S., Farzadfar, F., Oliver, J., Ezzati, M., & Moran, A. (2013). Worldwide risk factors for heart failure: A systematic review and pooled analysis. International Journal of Cardiology, 168(2), 1186–1194. https://doi.org/10.1016/j.ijcard.2012.11.065
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., ... ESC Scientific Document Group. (2021). 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), 3599–3726. https://doi.org/10.1093/eurheartj/ehab368
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M. R., & PARADIGM-HF Committees Investigators. (2014). Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). European Journal of Heart Failure, 16(7), 817–825. https://doi.org/10.1002/ejhf.115
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., ... DAPA-HF Trial Committees and Investigators. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. The New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/NEJMoa1911303
Mullens, W., Damman, K., Harjola, V.-P., Mebazaa, A., Brunner-La Rocca, H.-P., Martens, P., Testani, J. M., Tang, W. H. W., Orso, F., Rossignol, P., Metra, M., Filippatos, G., Seferovic, P. M., Ruschitzka, F., & Coats, A. J. (2019). The use of diuretics in heart failure with congestion: A position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 21(2), 137–155. https://doi.org/10.1002/ejhf.1369
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D.-J., Chopra, V., ... EMPEROR-Reduced Trial Investigators. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. The New England Journal of Medicine, 383(15), 1413–1424. https://doi.org/10.1056/NEJMoa2022190
Park, J. J. (2021). Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes. Diabetes & Metabolism Journal, 45(2), 146–157. https://doi.org/10.4093/dmj.2020.0282
Pieske, B., Maggioni, A. P., Lam, C. S. P., Pieske-Kraigher, E., Filippatos, G., Butler, J., Ponikowski, P., Shah, S. J., Solomon, S. D., Scalise, A.-V., Mueller, K., Roessig, L., & Gheorghiade, M. (2017). Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: Results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 38(15), 1119–1127. https://doi.org/10.1093/eurheartj/ehw593
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G. M. C., Ruilope, L. M., Ruschitzka, F., ... ESC Scientific Document Group. (2016). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129–2200. https://doi.org/10.1093/eurheartj/ehw128
Regitz-Zagrosek, V. (2020). Sex and gender differences in heart failure. International Journal of Heart Failure, 2(3), 157–181. https://doi.org/10.36628/ijhf.2020.0004
Sapna, F., Raveena, F., Chandio, M., Bai, K., Sayyar, M., Varrassi, G., Khatri, M., Kumar, S., & Mohamad, T. (2023). Advancements in heart failure management: A comprehensive narrative review of emerging therapies. Cureus, 15(10), Article e46486. https://doi.org/10.7759/cureus.46486
Shahim, B., Kapelios, C. J., Savarese, G., & Lund, L. H. (2023). Global public health burden of heart failure: An updated review. Cardiac Failure Review, 9, Article e11. https://doi.org/10.15420/cfr.2023.05
Shams, P., Malik, A., & Chhabra, L. (2025). Heart failure (congestive heart failure). In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK430873/
Sharifi-Rad, J., Rodrigues, C. F., Sharopov, F., Docea, A. O., Can Karaca, A., Sharifi-Rad, M., Kahveci Karıncaoglu, D., Gülseren, G., Şenol, E., Demircan, E., Taheri, Y., Suleria, H. A. R., Özçelik, B., Nur Kasapoğlu, K., Gültekin-Özgüven, M., Daşkaya-Dikmen, C., Cho, W. C., Martins, N., & Calina, D. (2020). Diet, lifestyle and cardiovascular diseases: Linking pathophysiology to cardioprotective effects of natural bioactive compounds. International Journal of Environmental Research and Public Health, 17(7), Article 2326. https://doi.org/10.3390/ijerph17072326
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., ... Langkilde, A. M. (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. The New England Journal of Medicine, 387(12), 1089–1098. https://doi.org/10.1056/NEJMoa2206286
Sukhbaatar, P., Bayartsogt, B., Ulziisaikhan, G., Byambatsogt, B., Khorloo, C., Badrakh, B., Tserendavaa, S., Sodovsuren, N., Dagva, M., Khurelbaatar, M.-U., Tsedensodnom, S., Nyamsuren, B.-E., Myagmardorj, R., & Unurjargal, T. (2023). The prevalence and risk factors of chronic heart failure in the Mongolian population. Diagnostics, 13(5), Article 999. https://doi.org/10.3390/diagnostics13050999
Trujillo, M. E., Ayalasomayajula, S., Blaustein, R. O., & Gheyas, F. (2023). Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science. Clinical and Translational Science, 16(12), 2458–2466. https://doi.org/10.1111/cts.13677
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., Commodore-Mensah, Y., Elkind, M. S. V., Evenson, K. R., Eze-Nliam, C., Fugar, S., Generoso, G., Heard, D. G., Hiremath, S., ... American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. (2023). Heart disease and stroke statistics—2023 update: A report from the American Heart Association. Circulation, 147(8), e93–e621. https://doi.org/10.1161/CIR.0000000000001123
Vannuccini, F., Campora, A., Barilli, M., & Palazzuoli, A. (2022). Vericiguat in heart failure: Characteristics, scientific evidence and potential clinical applications. Biomedicines, 10(10), Article 2471. https://doi.org/10.3390/biomedicines10102471
Yan, S., Deng, P., Chai, K., Wang, S., Hu, K., Yang, J., & Wang, H. (2025). Global, regional, and national burden of heart failure and its risk factors between 1990 and 2021 and projections to 2050: An analysis of the Global Burden of Disease Study. European Heart Journal - Quality of Care and Clinical Outcomes, 11(7), 1144–1154. https://doi.org/10.1093/ehjqcco/qcaf054
Zhang, S., Liu, C., Zhang, Y., Wu, Z., Feng, K., Lai, Y., Pei, J., & Guan, T. (2023). Different heart failure phenotypes of valvular heart disease: The role of mitochondrial dysfunction. Frontiers in Cardiovascular Medicine, 10, Article 1135938. https://doi.org/10.3389/fcvm.2023.1135938
Ziaeian, B., & Fonarow, G. C. (2016). Epidemiology and aetiology of heart failure. Nature Reviews Cardiology, 13(6), 368–378. https://doi.org/10.1038/nrcardio.2016.25
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Radosław Szydłowski, Magdalena Bodera, Anna Kaźmierska, Hanna Porwolik, Sonja Rozmus, Dominik Bylica
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
